行情

IBIO

IBIO

IBIO
AMEX

实时行情|Nasdaq Last Sale

0.2401
0.0000
0.00%
盘后: 0.2449 +0.0048 +2.00% 19:22 05/25 EDT
开盘
0.2410
昨收
0.2401
最高
0.2420
最低
0.2370
成交量
129.28万
成交额
0
52周最高
1.755
52周最低
0.2230
市值
5,238.16万
市盈率(TTM)
-1.5724
分时
5日
1月
3月
1年
5年
美股抗疫概念股普跌
美股抗疫概念股普跌
格隆汇 · 2021/12/27 15:11
美股开盘 | 三大指数涨跌不一,360数科(QFIN.US)涨超9%
美股开盘 | 三大指数涨跌不一,360数科(QFIN.US)涨超9%
智通财经 · 2021/07/09 13:30
美股前瞻 | 三大股指期货齐涨,热门中概股盘前上扬
美股前瞻 | 三大股指期货齐涨,热门中概股盘前上扬
智通财经 · 2021/07/09 12:00
暂无数据
了解IBIO最新的财务预测,通过IBIO每股收益,每股净资产,每股现金流等数据分析IBIO近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
100.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测IBIO价格均价为1.750,最高价位2.500,最低价为1.000。
最高2.500
均价1.750
最低1.000
现价0.2401
EPS
实际EPS
预期EPS
-0.06-0.04-0.03-0.01
    0
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
机构持股
总机构数: 16
机构持股: 33.22万
持股比例: 0.15%
总股本: 2.18亿
类型机构数股数
增持
4
1.41万
建仓
2
1.98万
减持
3
6,983
平仓
1
250
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.11%
制药与医学研究
+0.01%
高管信息
Chairman/President/Chief Executive Officer/Director
Thomas Isett
Chief Financial Officer/Chief Accounting Officer
Robert Lutz
Chief Scientific Officer
Martin Brenner
Independent Director
Linda Armstrong
Independent Director
Glenn Chang
Independent Director
William Clark
Independent Director
James Hill
Independent Director
Alexandra Kropotova
Independent Director
John McKey
Independent Director
Evert Schimmelpennink
Independent Director
Gary Sender
暂无数据
暂无数据
IBIO 简况
iBio, Inc. is a developer of biopharmaceuticals and FastPharming Manufacturing System. The Company is applying its technologies to develop product candidates to treat or prevent fibrotic diseases, cancers, and infectious diseases. The Company is using its FastPharming Manufacturing System (FastPharming System) and Glycaneering Services to build a portfolio of biologic drug candidates. The Company is also using the FastPharming System to create proteins for others by contract through the Company’s catalog. The Company operates through two segments: Biopharmaceuticals and Bioprocessing. Its Biopharmaceuticals segment, which includes development and licensing in two business units: therapeutics and vaccines. Its Bioprocessing, which includes services and products for research and further manufacturing uses, collectively known as Research & Bioprocess products (RBP). Its pipeline includes IBIO-100, IBIO-101, IBIO-202 and IBIO-400.

微牛提供Ibio Inc(AMEX-IBIO)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的IBIO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易IBIO股票基本功能。